Human Anti-KIR3DL2 Recombinant Antibody (
8D10) (V2LY-0725-LY804)

Name: Human Anti-KIR3DL2 Recombinant Antibody (8D10)
SKU: V2LY-0725-LY804
Rating: 5 (1 reviews)

See all KIR3DL2 antibodies

Compare Online Inquiry

Tested Data

Human Anti-KIR3DL2 Recombinant Antibody (8D10) (V2LY-0725-LY804) in ELISA

The Binding Activity of Human KIR3DL2 with Anti-KIR3DL2 Recombinant AntibodyActivity: Measured by its binding ability in a functional ELISA. Immobilized Human KIR3DL2 at 2 μg/mL can bind Anti-KIR3DL2 recombinant antibody , the EC50 is 14.18-23.93 ng/mL.

Human Anti-KIR3DL2 Recombinant Antibody (8D10) (V2LY-0725-LY804) in FC

Untransfected HEK-293T cells (green line) and transfected Human KIR3DL2 HEK-293T stable cells (red line) were stained with anti-KIR3DL2 recombinant antibody (2µg/1*106cells), washed and then followed by FITC-conjugated anti-Human IgG Fc antibody and analyzed with flow cytometry.

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Human

Clone

8D10

Application

ELISA, FC

Immunogen

Recombinant Human KIR3DL2 protein.

Host Species

Human

Specificity

Human

Antibody Isotype

IgG1

Clonality

Monoclonal Antibody

Application Notes

Application	Note
FC	1:20-1:200

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, Glycerol

Preservative

Sodium azide

Concentration

Batch dependent

Purity

> 95% Purity determined by SDS-PAGE.

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

More Infomation

Target

Full Name

Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 2

Entrez Gene ID

3812

UniProt ID

P43630

Function

Receptor on natural killer (NK) cells and T cells for MHC class I molecules (PubMed:24018270, PubMed:28636952).
Upon binding of peptide-free HLA-F open conformer, negatively regulates NK and T cell effector functions (PubMed:24018270).
Acts as a receptor on astrocytes for HLA-F. Through interaction with HLA-F, may protect motor neurons from astrocyte-induced toxicity (PubMed:26928464).

Biological Process

Cellular defense responseManual Assertion Based On ExperimentTAS:ProtInc
Negative regulation of neuron deathManual Assertion Based On ExperimentIMP:UniProtKB

Cellular Location

Cell membrane

Topology

Extracellular: 22-340
Helical: 341-360
Cytoplasmic: 361-455

Decroos, A., Cheminant, M., Bruneau, J., Carras, S., Parinet, V., Pelletier, L., ... & Ortonne, N. (2023). KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma. Haematologica, 108(10), 2830.

Cheminant, M., Lhermitte, L., Bruneau, J., Sicard, H., Bonnafous, C., Touzart, A., ... & Hermine, O. (2022). KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target. Blood, The Journal of the American Society of Hematology, 140(13), 1522-1532.

Roelens, M., de Masson, A., Ram‐Wolff, C., Maki, G., Cayuela, J. M., Marie‐Cardine, A., ... & Moins‐Teisserenc, H. (2020). Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker. British Journal of Dermatology, 182(6), 1415-1422.

Wu, Y., Yang, S., Liu, H., Luo, S., Stinchcombe, T. E., Glass, C., ... & Wei, Q. (2020). Novel genetic variants of KIR3DL2 and PVR involved in immunoregulatory interactions are associated with non-small cell lung cancer survival. American journal of cancer research, 10(6), 1770.

Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B. M., Vermeer, M., ... & Kim, Y. H. (2019). IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. The Lancet Oncology, 20(8), 1160-1170.

Van Der Weyden, C., Bagot, M., Neeson, P., Darcy, P. K., & Prince, H. M. (2018). IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Investigational Drugs, 27(8), 691-697.

Hurabielle, C., Leboeuf, C., Ram‐Wolff, C., Meignin, V., Rivet, J., Vignon‐Pennamen, M. D., ... & Battistella, M. (2018). KIR3DL2 expression in patients with adult T‐cell lymphoma/leukaemia. British Journal of Dermatology, 179(1), 197-199.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Anti-KIR3DL2 Recombinant Antibody (
8D10)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-KIR3DL2 Recombinant Antibody (539304) (CAT#: CBMAB-K0114-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry